Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors.
Preparation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]-guanine ([18F]-FHPG) for clinical use, and its evaluation as a positron emission tomography (PET) imaging agent for gene incorporation and expression in tumors are reported. In vitro studies in human colon cancer cells, HT-29, transduced with the retroviral vector G1Tk1SvNa and nontransduced (wild type) showed 4, 8, 12, and 15 times higher uptake of the probe in 1, 3, 5, and 7 h, respectively, in transduced cells compared with the controls. In vivo studies in tumor-bearing nude mice demonstrated that the tumor uptake of the radiotracer is three and six-fold higher in 2 and 5 h, respectively, in transduced cells compared with the control cells. These results suggest that [18F]-FHPG is a potential in vivo PET imaging agent for monitoring gene incorporation and expression in gene therapy of cancer.
Alauddin
M M
MM
PET Imaging Science Center, University of Southern California Norris Comprehensive Cancer Center, Los Angeles 90033, USA.
Shahinian
A
A
Kundu
R K
RK
Gordon
E M
EM
Conti
P S
PS
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D005462:Fluorine Radioisotopes; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D015316:Genetic Therapy; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000628:therapy*; D014055:Tomography, Emission-Computed
C104325:9-((3-fluoro-1-hydroxy-2-propoxy)methyl)guanine; D005462:Fluorine Radioisotopes; D015774:Ganciclovir